| Literature DB >> 35094024 |
Hang Zhou1,2, Rasmon Kalayasiri3,4,5, Yan Sun6, Yaira Z Nuñez1,2, Hong-Wen Deng7, Xiang-Ding Chen8, Amy C Justice9,10, Henry R Kranzler11,12, Suhua Chang13, Lin Lu6,13, Jie Shi6, Kittipong Sanichwankul14, Apiwat Mutirangura5, Robert T Malison1, Joel Gelernter15,16,17.
Abstract
Alcohol use disorder (AUD) is a leading cause of death and disability worldwide. Genome-wide association studies (GWAS) have identified ~30 AUD risk genes in European populations, but many fewer in East Asians. We conducted GWAS and genome-wide meta-analysis of AUD in 13,551 subjects with East Asian ancestry, using published summary data and newly genotyped data from five cohorts: (1) electronic health record (EHR)-diagnosed AUD in the Million Veteran Program (MVP) sample; (2) DSM-IV diagnosed alcohol dependence (AD) in a Han Chinese-GSA (array) cohort; (3) AD in a Han Chinese-Cyto (array) cohort; and (4) two AD Thai cohorts. The MVP and Thai samples included newly genotyped subjects from ongoing recruitment. In total, 2254 cases and 11,297 controls were analyzed. An AUD polygenic risk score was analyzed in an independent sample with 4464 East Asians (Genetic Epidemiology Research in Adult Health and Aging (GERA)). Phenotypes from survey data and ICD-9-CM diagnoses were tested for association with the AUD PRS. Two risk loci were detected: the well-known functional variant rs1229984 in ADH1B and rs3782886 in BRAP (near the ALDH2 gene locus) are the lead variants. AUD PRS was significantly associated with days per week of alcohol consumption (beta = 0.43, SE = 0.067, p = 2.47 × 10-10) and nominally associated with pack years of smoking (beta = 0.09, SE = 0.05, p = 4.52 × 10-2) and ever vs. never smoking (beta = 0.06, SE = 0.02, p = 1.14 × 10-2). This is the largest GWAS of AUD in East Asians to date. Building on previous findings, we were able to analyze pleiotropy, but did not identify any new risk regions, underscoring the importance of recruiting additional East Asian subjects for alcohol GWAS.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35094024 PMCID: PMC9372033 DOI: 10.1038/s41386-022-01265-w
Source DB: PubMed Journal: Neuropsychopharmacology ISSN: 0893-133X Impact factor: 8.294
Sample characteristics.
| Cohorts | Traits | # Cases | Mean (SD), Age | Country of recruitment | |
|---|---|---|---|---|---|
| Thai METH–GSA | DSM-IV AD | 532 (49.4) | 127 | 26.6 (6.9) | Thailand |
| Thai METH–MEGA | DSM-IV AD | 2370 (42.5) | 794 | 34.7 (10.1) | Thailand |
| MVP–EAA | ICD-9/10 AUD | 6955 (10.7) | 701 | 53.4 (17.1) | United States |
| Han Chinese–GSA | DSM-IV AD | 3381 (29.9) | 533 | 34.2 (8.3) | China |
| Han Chinese–Cyto | DSM-IV AD | 313 (0) | 99 | 49.6 (14.7) | China |
| Total | 13,551 | 2254 |
Thai METH studies of the genetics of methamphetamine dependence in Thailand, GSA Global Screening Array, MEGA Multi-Ethnic Global Array, EAA East Asian American, Cyto Cyto12 array, AD alcohol dependence, AUD alcohol use disorder.
Tested phenotypes in GERA and association results with AUD PRS.
| Traits | Distribution | Beta (SE) | |
|---|---|---|---|
| Alcohol use in days per week | 1 = 2757, 2 = 603, 3 = 503, 4 = 159, 5 = 267c | 0.43 (0.07) | |
| Smoking in pack years | 0 = 3232, 1 = 530, 2 = 306, 3 = 128, 4 = 44d | 0.09 (0.05) | |
| Ever vs. never smoked | 1 = 1055, 0 = 3232 | 0.06 (0.02) | |
| Former vs. current smoker | 1 = 924, 0 = 131 | −0.04 (0.04) | 2.50 × 10−1 |
| Physical activity | 1 = 897, 2 = 958, 3 = 1181, 4 = 1323e | 0.02 (0.06) | 7.97 × 10−1 |
| Health status | 1 = 740, 2 = 1506, 3 = 1625, 4 = 476 f | 0.03 (0.05) | 5.23 × 10−1 |
| Disease or conditions | |||
| Acute reaction to stress | 1 = 275, 0 = 4189 | −0.01 (0.01) | 5.22 × 10−1 |
| Allergic rhinitis | 1 = 1307, 0 = 3157 | 0.01 (0.03) | 5.62 × 10−1 |
| Asthma | 1 = 654, 0 = 3810 | −0.01 (0.02) | 7.21 × 10−1 |
| Cancer: anya | 1 = 529, 0 = 3935 | −0.00 (0.02) | 9.36 × 10−1 |
| Cardiovascular disease: anyb | 1 = 688, 0 = 3776 | −0.03 (0.02) | 1.48 × 10−1 |
| Major depressive disorder | 1 = 262, 0 = 4202 | 0.01 (0.01) | 3.66 × 10−1 |
| Dermatophytosis | 1 = 374, 0 = 4090 | −0.01 (0.02) | 4.87 × 10−1 |
| Type II diabetes | 1 = 729, 0 = 3735 | 0.03 (0.02) | 9.65 × 10−2 |
| Dyslipidaemia | 1 = 2192, 0 = 2272 | −0.02 (0.03) | 5.17 × 10−1 |
| Hemorrhoids | 1 = 716, 0 = 3748 | 0.01 (0.02) | 6.19 × 10−1 |
| Hernia abdominopelvic cavity | 1 = 177, 0 = 4287 | 0.00 (0.01) | 7.54 × 10−1 |
| Hypertensive disease | 1 = 2028, 0 = 2436 | −0.00 (0.02) | 9.52 × 10−1 |
| Insomnia | 1 = 185, 0 = 4279 | −0.01 (0.01) | 2.30 × 10−1 |
| Iron deficiency anemias | 1 = 118, 0 = 4346 | 0.00 (0.01) | 9.14 × 10−1 |
| Irritable bowel syndrome | 1 = 103, 0 = 4361 | 0.00 (0.01) | 7.05 × 10−1 |
| Macular degeneration | 1 = 130, 0 = 4334 | −0.00 (0.01) | 7.94 × 10−1 |
| Osteoarthritis | 1 = 941, 0 = 3523 | −0.01 (0.02) | 6.72 × 10−1 |
| Osteoporosis | 1 = 392, 0 = 4072 | 0.01 (0.01) | 6.46 × 10−1 |
| Psychiatric disorder: any | 1 = 433, 0 = 4031 | −0.00 (0.02) | 9.93 × 10−1 |
| Peripheral vascular disease | 1 = 160, 0 = 4304 | 0.01 (0.01) | 3.81 × 10−1 |
If not specified for distribution, 1 is case and 0 is control. Traits with p value < 0.05 are labled in bold font..
aCancer: includes malignant tumors, neoplasms, lymphoma and sarcoma.
bHeart disease: includes ischemic heart disease, cardiac arrest, congestive health failure, dysrhythmias, cardiomyopathy, aortic aneurysm, and cerebrovascular disease, but excludes PVD which is encompassed by the PVD variable.
cDays of alcohol intake per week, 1 is no days, 2 is 1 day, 3 is 2–4 days, 4 is 5–6 days, 5 is every day.
dPack years for former or current smoker, 0 = 0, 1 < 10, 2 = 10–20, 3 = 20–30, 4 ≥ 30.
ePhysical activity total metabolic equivalency of task (MET), 1 = first quartile, 0–173 for males and 0–74 for females, 2 = second quartile, 174–600 for males and 75–344 for females, 3 = third quartile, 601–1380 for males and 345–983 for females, 4 = fourth quartile, 1381+ for males and 984+ for females.
fHealth status, 1 = excellent, 2 = very good, 3 = good, 4 = fair.
Fig. 1Association results for AUD meta-analyses.
a Manhattan plot for AUD, ncase = 2254, ncontrol = 11,297. Effective sample size-weighted meta-analyses were performed using METAL. Red line indicates genome-wide significant after correction for multiple testing (p < 5 × 10–8), blue line indicates suggestive significant (p < 1 × 10–5). b QQ plot for AUD.
Fig. 2Regional Manhattan plots for the top SNPs.
a Regional plot for rs1229984 in East Asians. b Regional plot for rs1229984 in European populations in a previous study (Zhou et al. [14]). c Regional plot for rs1229984 in African Americans from a previous MVP study (Kranzler et al. [8]) where rs1229984 is nominally significant, rs2066702 is the lead variant. In total, 500 kb in the upstream and downstream of rs1229984 were presented in a–c. d Regional plot for rs3782886 in East Asians. Given the high LD in this region, 1 Mb from both sides were extended.